AveXis, Inc. Expected to Post Q3 2017 Earnings of ($1.35) Per Share (AVXS)

AveXis, Inc. (NASDAQ:AVXS) – Analysts at William Blair issued their Q3 2017 earnings per share estimates for AveXis in a research report issued to clients and investors on Wednesday. William Blair analyst R. Prasad expects that the company will post earnings per share of ($1.35) for the quarter. William Blair currently has a “Outperform” rating and a $107.00 price objective on the stock. William Blair also issued estimates for AveXis’ Q4 2017 earnings at ($1.39) EPS, FY2017 earnings at ($5.88) EPS, FY2018 earnings at ($6.41) EPS, FY2019 earnings at ($6.80) EPS, FY2020 earnings at ($5.00) EPS and FY2021 earnings at $7.05 EPS.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing the consensus estimate of ($0.97) by $1.10. During the same quarter in the previous year, the business posted ($0.68) EPS.

Several other brokerages have also commented on AVXS. Morgan Stanley reissued an “overweight” rating and set a $118.00 price objective on shares of AveXis in a report on Wednesday, August 9th. Evercore ISI began coverage on AveXis in a report on Wednesday, August 16th. They set an “outperform” rating and a $120.00 price objective for the company. Chardan Capital reissued a “buy” rating and set a $130.00 price objective (up previously from $102.50) on shares of AveXis in a report on Friday, August 11th. BMO Capital Markets reissued a “buy” rating and set a $123.00 price objective on shares of AveXis in a report on Friday, August 11th. Finally, Sanford C. Bernstein began coverage on AveXis in a report on Thursday, July 27th. They set an “outperform” rating and a $108.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $102.83.

Shares of AveXis (AVXS) opened at 97.25 on Friday. The firm’s market cap is $3.10 billion. The firm has a 50-day moving average of $89.48 and a 200 day moving average of $76.66. AveXis has a 52-week low of $32.31 and a 52-week high of $99.45.

In related news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $91.52, for a total value of $162,905.60. Following the completion of the sale, the vice president now owns 1,780 shares in the company, valued at approximately $162,905.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 5,340 shares of company stock valued at $434,872 in the last 90 days. 18.60% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Quantitative Systematic Strategies LLC purchased a new stake in AveXis during the first quarter worth $201,000. Candriam Luxembourg S.C.A. purchased a new stake in AveXis during the first quarter worth $1,901,000. Credit Suisse AG increased its stake in AveXis by 36.4% in the first quarter. Credit Suisse AG now owns 63,228 shares of the company’s stock worth $4,807,000 after buying an additional 16,876 shares during the last quarter. Swiss National Bank increased its stake in AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock worth $2,083,000 after buying an additional 800 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in AveXis by 11.7% in the first quarter. Vanguard Group Inc. now owns 1,194,809 shares of the company’s stock worth $90,841,000 after buying an additional 124,750 shares during the last quarter. Institutional investors own 91.85% of the company’s stock.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.